Know Cancer

or
forgot password

Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients


N/A
N/A
N/A
Open (Enrolling)
Both
Neoplasms

Thank you

Trial Information

Interindividual Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Oncology/Bone Marrow Transplantation Patients


The title of this study is interindividual genetic variability as a determinant of
chemotherapy toxicity and response in pediatric oncology/bone marrow transplantation
patients. We will collect blood from pediatric oncology/bone marrow transplantation patients
who are going to receive chemotherapy in order to assess several defined genetic
polymorphisms that may be involved in chemotherapy toxicity and response. The polymorphisms
will be assessed on normal mononuclear cells by a combination of techniques. We will
determine whether these polymorphisms occur in pediatric oncology/bone marrow
transplantation patients and their correlation with different clinical features during and
following therapy including toxicity and response. The presence or absence of polymorphisms
will be correlated with patient outcome and tumor recurrence.


Inclusion Criteria:



- All Pediatric Oncology and Bone Marrow Transplantation Service patients with a
histologically proven tumor for whom there is an intent to treat with chemotherapy
are eligible for participation in this study. The patient does not need to be newly
diagnosed for enrollment on this protocol.

- All patients or their guardians must provide written informed consent. Minors will be
required to provide assent.

Exclusion Criteria:

- None

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

To determine if genetic polymorphisms are associated with the presence and extent of chemotherapy related toxicity in pediatric bone marrow transplantation patients and the response and outcome of these patients.

Outcome Time Frame:

12 months

Safety Issue:

Yes

Principal Investigator

Paul Meyers, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

03-123

NCT ID:

NCT00578630

Start Date:

October 2003

Completion Date:

December 2014

Related Keywords:

  • Neoplasms
  • pediatric tumors
  • genetic test development
  • All Pediatric patients with a histologically proven tumor.
  • Neoplasms

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021